The British Generic Manufacturers Association has responded to the latest UK statements on plans for free trade agreements with non-EU nations in the wake of Brexit by emphasizing that the country must not accept any changes to patent or exclusivity provisions that could delay the market entry of generics and biosimilars in the UK.
BGMA Urges UK To Hold Firm On Trade Deals
Insists Patent And Exclusivity Provisions Must Not Block Access
Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.
More from Legal & IP
• By
Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.
• By
With sales of $550m last year and a high barrier to entry, Exparel marks an intriguing target for abbreviated new drug application sponsors. Having shot down a US patent last year and won US FDA approval for its ANDA, Jiangsu Hengrui’s US eVenus Pharmaceutical Laboratories subsidiary and partner Fresenius Kabi have just reached a settlement agreement.
• By
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
• By
Spanish competition regulator the CNMC has announced an investigation into Sandoz and its Bexal subsidiary – as well as Alliance Healthcare España and Bluetab Solutions – over sharing sensitive commercial information relating to pharmacy orders for generics.